Abstract
The field of immuno-oncology has gained great interest. Novel immune-enhancing treatment modalities against cancer have been approved for some solid cancers, especially in malignant melanomas and non-small-cell lung cancer, showing promising results on patient survival. Research in the area of immunotherapy is still ongoing and yet to be approved for some gastrointestinal cancers.
With the continuous advances in immuno-oncology, immunodiagnostic tests, in which the immune-related features of a malignant tumor are characterized, play a crucial role. Immunodiagnosis seek to identify both local and systemic characteristics of a malignancy. Immunodiagnostic tests may assist in cancer prognostication and in the selection of oncological treatment for patients with cancer. For instance, the density of tumor-infiltrating lymphocytes (TILs), especially CD8+ T cells have been correlated with improved prognosis in patients with gastrointestinal (GI) cancers. Likewise, a high infiltration of FoxP3+ lymphocytes has been associated with poor prognosis in different cancers, including upper GI cancers. The role of programmed death-ligand 1 (PD-L1) and tumor mutational burden (TMB) in upper GI cancers are yet to be considered as standard-of care biomarkers for prognosis and treatment response to immune-enhancing therapies.
In this chapter, novel immunodiagnostic approaches for upper GI cancers will be presented and discussed in detail. The future aspects of immuno-oncology in upper GI cancers will also be discussed. The chapter will especially focus on how the local features (in the tumor microenvironment) of upper GI cancers can be examined through immunodiagnostic tests to determine prognosis and treatment response to immunotherapy.
This is a preview of subscription content, log in via an institution to check access.
References
Abrha A, Shukla ND, Hodan R, Longacre T, Raghavan S, Pritchard CC, Fisher G, Ford J, Haraldsdottir S (2020) Universal screening of gastrointestinal malignancies for mismatch repair deficiency at Stanford. JNCI Cancer Spectr 4:5. https://doi.org/10.1093/JNCICS/PKAA054
Ahmed S, Bradshaw AD, Gera S, Zahidunnabi Dewan M, Xu R (2017) The TGF-β/Smad4 signaling pathway in pancreatic carcinogenesis and its clinical significance. J Clin Med 6(1):5. https://doi.org/10.3390/JCM6010005
Akinleye A, Rasool Z (2019) Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 12(1):1–13. https://doi.org/10.1186/S13045-019-0779-5/TABLES/3
Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, Bray F (2020) Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 159(1):335–349.e15. https://doi.org/10.1053/J.GASTRO.2020.02.068
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17(9):557–588. https://doi.org/10.1038/s41575-020-0310-z
Batlle E, Massagué J (2019) Immunity review transforming growth factor-b signaling in immunity and cancer. https://doi.org/10.1016/j.immuni.2019.03.024
Bhuva N, Li S, Jane M (2012) Living with and beyond cancer: new challenges. IntechOpen. https://doi.org/10.5772/24959
Bournet B, Muscari F, Buscail C, Assenat E, Barthet M, Hammel P, Selves J, Guimbaud R, Cordelier P, Buscail L (2016) KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma. Clin Transl Gastroenterol 7(3):e157. https://doi.org/10.1038/CTG.2016.18
Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465. https://doi.org/10.1056/NEJMOA1200694/SUPPL_FILE/NEJMOA1200694_DISCLOSURES.PDF
Brar G, Shah MA (2019) The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. Ther Adv Gastroenterol 12:1756284819869767. https://doi.org/10.1177/1756284819869767
Buscail L, Bournet B, Cordelier P (2020) Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol 17(3):153–168. https://doi.org/10.1038/s41575-019-0245-4
Castle JC, Uduman M, Pabla S, Stein RB, Buell JS (2019) Mutation-derived neoantigens for cancer immunotherapy. Front Immunol 10:1856. https://doi.org/10.3389/FIMMU.2019.01856/BIBTEX
Castro F, Cardoso AP, Gonçalves RM, Serre K, Oliveira MJ (2018) Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol 9:847. https://doi.org/10.3389/FIMMU.2018.00847/BIBTEX
Chang E, Pelosof L, Lemery S, Gong Y, Goldberg KB, Farrell AT, Keegan P, Veeraraghavan J, Wei G, Blumenthal GM, Amiri-Kordestani L, Singh H, Fashoyin-Aje L, Gormley N, Kluetz PG, Pazdur R, Beaver JA, Theoret MR (2021) Systematic review of PD-1/PD-L1 inhibitors in oncology: from personalized medicine to public health. Oncologist 26(10):e1786–e1799. https://doi.org/10.1002/ONCO.13887
Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J, Liu Z, Wang J, Qian Y, Cui P, Huang D, Huang Z, Wu Z, Hu Y (2021) Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. Front Oncol 11:1128. https://doi.org/10.3389/FONC.2021.562315/BIBTEX
Davis A, Patel VG (2019) The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer 7(1):278. https://doi.org/10.1186/S40425-019-0768-9
Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, Solcia E, Sessa F, Fleitas T, Freeman GJ, Rodig SJ, Rabkin CS, Bass AJ, Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, Solcia E, Sessa F, Fleitas T, Freeman GJ, Rodig SJ, Rabkin CS, Bass AJ (2016) Abundant PD-L1 expression in Epstein-Barr virus-infected gastric cancers. Oncotarget 7(22):32925–32932. https://doi.org/10.18632/ONCOTARGET.9076
Derynck R, Akhurst RJ (2007) Differentiation plasticity regulated by TGF-β family proteins in development and disease. Nat Cell Biol 9(9):1000–1004. https://doi.org/10.1038/ncb434
Ding W, Xu X, Qian Y, Xue W, Wang Y, Du J, Jin L, Tan Y (2018) Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma a meta-analysis. Medicine (United States) 97:50. https://doi.org/10.1097/MD.0000000000013301
Duffy AG, Greten TF (2017) Treating hepatobiliary cancer: the immunologic approach. Dig Dis 35(4):390–396. https://doi.org/10.1159/000456593
Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12(1):19–23. https://doi.org/10.1007/S003840050072
Eso Y, Seno H (2020) Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers. Ther Adv Gastroenterol 13:1756284820948773. https://doi.org/10.1177/1756284820948773
Farhood B, Najafi M, Mortezaee K (2019) CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 234(6):8509–8521. https://doi.org/10.1002/jcp.27782
Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by Indoleamine 2,3-dioxygenase. J Exp Med 196(4):459–468. https://doi.org/10.1084/JEM.20020121
Funkhouser WK, Lubin IM, Monzon FA, Zehnbauer BA, Evans JP, Ogino S, Nowak JA (2012) Relevance, pathogenesis, and testing algorithm for mismatch repair–defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn 14(2):91–103. https://doi.org/10.1016/J.JMOLDX.2011.11.001
Gaddam S, Abboud Y, Oh J, Samaan JS, Nissen NN, Lu SC, Lo SK (2021) Incidence of pancreatic cancer by age and sex in the US, 2000–2018. JAMA 326(20):2075. https://doi.org/10.1001/jama.2021.18859
Galon J, Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 18(3):197–218. https://doi.org/10.1038/s41573-018-0007-y
Galon J, Bruni D (2020) Tumor immunology and tumor evolution: intertwined histories. Immunity 52:55–81
Gandhi L, RodrÃguez-Abreu D, Gadgeel S, Esteban E, Felip E, de Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY-S, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC (2018) Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med 378(22):2078–2092. https://doi.org/10.1056/NEJMOA1801005/SUPPL_FILE/NEJMOA1801005_DISCLOSURES.PDF
Gao Y, Guo W, Geng X, Zhang Y, Zhang G, Qiu B, Tan F, Xue Q, Gao S, He J (2020) Prognostic value of tumor-infiltrating lymphocytes in esophageal cancer: an updated meta-analysis of 30 studies with 5,122 patients. Ann Transl Med 8(13):822. https://doi.org/10.21037/ATM-20-151
Ghidini M, Lampis A, Mirchev MB, Okuducu AF, Ratti M, Valeri N, Hahne JC (2020) Immune-based therapies and the role of microsatellite instability in pancreatic cancer. Genes 12(1):33. https://doi.org/10.3390/GENES12010033
Giuliano M, Shaikh A, Lo HC, Arpino G, de Placido S, Zhang XH, Cristofanilli M, Schiff R, Trivedi MV (2018) Perspective on circulating tumor cell clusters: why it takes a village to metastasize. Cancer Res 78(4):845–852. https://doi.org/10.1158/0008-5472.CAN-17-2748
Gough NR, Xiang X, Mishra L (2021) TGF-β Signaling in liver, pancreas, and gastrointestinal diseases and cancer. Gastroenterology 161(2):434–452.e15. https://doi.org/10.1053/J.GASTRO.2021.04.064
Hahn SA, Schutte M, Shamsul Hoque ATM, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1979) 271(5247):350–353. https://doi.org/10.1126/SCIENCE.271.5247.350
Haigis KM (2017) KRAS alleles: the devil is in the detail. Trends Cancer 3(10):686–697. https://doi.org/10.1016/J.TRECAN.2017.08.006
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A (2019) Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 30(4):582–588. https://doi.org/10.1093/annonc/mdz011
Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12(1):31–46. https://doi.org/10.1158/2159-8290.CD-21-1059
Hanahan D, Weinberg R (2011) Hallmarks of cancer: the next generation. Cell Press 144(5):646–674
Hause RJ, Pritchard CC, Shendure J, Salipante SJ (2016) Classification and characterization of microsatellite instability across 18 cancer types. Nature Med 22(11):1342–1350. https://doi.org/10.1038/nm.4191
Heredia-Soto V, RodrÃguez-Salas N, Feliu J (2021) Liquid biopsy in pancreatic cancer: are we ready to apply it in the clinical practice? Cancers 13(8):1986. https://doi.org/10.3390/CANCERS13081986
Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, Lowery MA, Diaz LA, Mandelker D, Yu KH, Zervoudakis A, Kelsen DP, Iacobuzio-Donahue CA, Klimstra DS, Saltz LB, Sahin IH, O’Reilly EM (2018) Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res 24(6):1326–1336. https://doi.org/10.1158/1078-0432.CCR-17-3099
Idos GE, Kwok J, Bonthala N, Kysh L, Gruber SB, Qu C (2020) The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a systematic review and meta-analysis. Sci Rep 10(1):1–14. https://doi.org/10.1038/s41598-020-60255-4
Javle M, Li Y, Tan D, Dong X, Chang P, Kar S, Li D (2014) Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer. PLoS One 9(1):e85942. https://doi.org/10.1371/JOURNAL.PONE.0085942
Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson AB, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK (2017) Annual report to the nation on the status of cancer, 1975–2014, featuring survival. JNCI: J Natl Cancer Inst 109:9. https://doi.org/10.1093/JNCI/DJX030
Jilkova ZM, Aspord C, Decaens T (2019) Predictive factors for response to PD-1/PD-L1 checkpoint inhibition in the field of hepatocellular carcinoma: current status and challenges. Cancers (Basel) 11:10. https://doi.org/10.3390/CANCERS11101554
Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Gail Eckhardt S (2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27(7):1130–1136. https://doi.org/10.1200/JCO.2008.19.8168
Karamitopoulou E (2019) Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br J Cancer 121(1):5–14. https://doi.org/10.1038/s41416-019-0479-5
Kelly RJ (2017) Immunotherapy for esophageal and gastric cancer. Am Soc Clin Oncol Educ Book 37:292–300. https://doi.org/10.1200/edbk_175231
Khan MA, Srivastava SK, Bhardwaj A, Singh S, Arora S, Zubair H, Carter JE, Singh AP (2015) Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: therapeutic implications. Oncotarget 6(36):39140–39150. https://doi.org/10.18632/oncotarget.3784
Laghi L, Beghelli S, Spinelli A, Bianchi P, Basso G, di Caro G, Brecht A, Celesti G, Turri G, Bersani S, Schumacher G, Roecken C, Graentzdoerffer I, Roncalli M, Zerbi A, Neuhaus P, Bassi C, Montorsi M, Scarpa A, Malesci A (2012) Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma. PLoS One 7:9. https://doi.org/10.1371/journal.pone.0046002
Lee JS, Ruppin E (2019) Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1. JAMA Oncol 5(11):1614–1618. https://doi.org/10.1001/jamaoncol.2019.2311
Lee JS, Won HS, Sun DS, Hong JH, Ko YH (2018) Prognostic role of tumor-infiltrating lymphocytes in gastric cancer a systematic review and meta-analysis. Medicine (United States) 97:32. https://doi.org/10.1097/MD.0000000000011769
Lee JS, Park SS, Lee YK, Norton JA, Jeffrey SS (2019) Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA. Mol Oncol 13(8):1623–1650. https://doi.org/10.1002/1878-0261.12537
Li K, Luo H, Huang L, Luo H, Zhu X (2020) Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int 20(1):1–13. https://doi.org/10.1186/S12935-019-1091-8/TABLES/3
Lin L, Kane N, Kobayashi N, Kono EA, Yamashiro JM, Nickols NG, Reiter RE (2020) High-dose per fraction radiotherapy induces both antitumor immunity and immunosuppressive responses in prostate tumors. https://doi.org/10.1158/1078-0432.CCR-20-2293
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7(1):1–28. https://doi.org/10.1038/s41572-020-00240-3
Lohneis P, Sinn M, Bischoff S, Juhling A, Pelzer U, Wislocka L, Bahra M, Sinn BV, Denkert C, Oettle H, Blaker H, Riess H, Johrens K, Striefler JK (2017) Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur J Cancer 83:290–301. https://doi.org/10.1016/j.ejca.2017.06.016
Long J, Wang A, Bai Y, Lin J, Yang X, Wang D, Yang X, Jiang Y, Zhao H (2019) Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine 42:363–374. https://doi.org/10.1016/J.EBIOM.2019.03.022/ATTACHMENT/51DE0214-C282-4535-B505-43AF711632C9/MMC10.DOCX
Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3(6):459–465. https://doi.org/10.1038/nrc1097
Mlecnik B, Bifulco C, Bindea G, Marliot F, Lugli A, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Gru tzmann R, van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han SJ, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Lafontaine L, Bruni D, Lanzi A, el Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Paustian C, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-Van Vliet S, Knijn N, Muşinǎ AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Fox BA, Pagès F, Galon J (2020) Multicenter international society for immunotherapy of cancer study of the consensus immunoscore for the prediction of survival and response to chemotherapy in stage III colon cancer. J Clin Oncol 38(31):3638–3651. https://doi.org/10.1200/JCO.19.03205
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G, Gomez Aubin G, Fein L, Kaen D, Kowalyszyn R, Lerzo G, Martinengo G, Molina M, Richardet E, Picon P, Varela M, Zarba JJ, de Azevedo SJ, Barrios CH, Beato C, Cerny CAS, de Marchi PRM, Fernandes G, Franke FA, Freitas H, Girotto G, Lopes V, Santos L, Costa MA, Shimada AK, Smaletz O, Soares JPH, Victorino AP, Ferreira C, Koleva M, Koynov K, Micheva R, Deliverski T, Milanova Z, Doganov B, Cheng S, de Angelis F, Speranza G, Juergens RA, Ksienski D, Fenton D, Aren O, Caglevic C, Galindo H, Rey F, Chang J, Chen G, Chen X, Ouyang X, Cheng Y, Ding Z, Hou M, Fan Y, Feng J, He J, He Y, Hu Y, Li W, Liu X, Liu Z, Lu S, Qin S, Tang Q, Wang B, Wang K, Zhang L, Zhang X, Zhao J, Wang J, Zhou C, Zhou J, Zhou Q, Cardona A, Duarte R, Gomez Wolff L, Zambrano A, Vallejo M, Havel L, Kolek V, Kolman P, Koubkova L, Petruzelka L, Popelkova P, Roubec J, Vanasek J, Vlasek T, Jaal J, Kuusk G, Avendano O, Castro H, Lopez K, Sandoval M, Ho CMJ, Lo SH, Laczo I, Piko B, Ostoros G, Aoe K, Fujisaka Y, Hirashima T, Horiike A, Hosomi Y, Hotta K, Ichiki M, Imamura F, Iwamoto Y, Kasahara K, Katakami N, Kato T, Murakami S, Kawaguchi T, Kishi K, Kurata T, Torii Y, Nakahara Y, Nishimura T, Ohira T, Saka H, Sawa T, Seki N, Sugawara S, Takahashi K, Takigawa N, Tanaka H, Yamada K, Yokoyama T, Yokoyama T, Yoshioka H, Purkalne G, Stara Z, Cesas A, Cicenas S, Zemaitis M, How SH, Liam CK, Ong CK, Tho LM, Arrieta Rodriguez O, de The Bustamante Valles F, Hernandez Hernandez C, Mas L, Vera L, Salas J, Tejada H, Edusma-Dy R, Galvez C, Ladrera GEI, Tan Chun Bing J, Jassem J, Kalinka-Warzocha E, Karaszewska B, Kazarnowicz A, Lesniewski Kmak K, Ramlau R, Araujo A, Barata F, Gil N, Hespanhol V, Alexandru A, Dediu M, Cherciu N, Ciurescu D, Ganea D, Miron L, Sirbu D, Turdean M, Emelyanov S, Karaseva N, Kuzina L, Lazarev S, Lifirenko I, Bolotina L, Lipatov O, Ovchinnikova E, Matrosova M, Alyasova A, Poltoratsky A, Taranov P, Zarubenkov O, Cohen G, Dreosti L, Seolwane F, Hall J, Hart G, Jordaan C, Buddu S, Botha M, Landers G, Rappaport B, Ruff P, Shepherd L, Szpak W, Ahn MJ, Kim JH, Bergstrom P, Ohman R, Griph H, Betticher D, Ochsenbein A, Zippelius A, Chan GC, Chiu CH, Hsia TC, Su WC, Yang CH, Ativitavas T, Danchaivijitr P, Seetalarom K, Sookprasert A, Sriuranpong V, Altundag O, Cay Senler F, Erman M, Goksel T, Goker E, Ozyilkan O, Seker M, Gumus M, Yumuk F, Adamchuk G, Ivashchuk O, Ponomarova O, Rusyn A, Shevnya S, Shparyk Y, Sinielnikov I, Andrusenko O, Trukhyn D, Ursol G, Vynnychenko I, Nguyen TQ, Pham XD (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393(10183):1819–1830. https://doi.org/10.1016/S0140-6736(18)32409-7
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu L-A, Waxman IM, Sharma P, Investigators C 025 (2015) Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813. https://doi.org/10.1056/NEJMoa1510665
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm M-O, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B (2018) Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290. https://doi.org/10.1056/NEJMoa1712126
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK (2019) Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103–1115. https://doi.org/10.1056/NEJMoa1816047
Mucileanu A, Chira R, Mircea PA (2021) PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies. Med Pharm Rep 94(4):402–410. https://doi.org/10.15386/MPR-2116
Napier KJ, Scheerer M, Misra S (2014) Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol 6(5):112–120. https://doi.org/10.4251/wjgo.v6.i5.112
Niu M, Yi M, Li N, Luo S, Wu K (2021) Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. Exp Hematol Oncol 10(1):1–13. https://doi.org/10.1186/S40164-021-00211-8
Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, Nakajima Y (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13(7):2151–2157. https://doi.org/10.1158/1078-0432.CCR-06-2746
Orhan A, Vogelsang RP, Andersen MB, Madsen MT, Hölmich ER, Raskov H, Gögenur I (2020) The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis. Eur J Cancer 132:71–84. https://doi.org/10.1016/j.ejca.2020.03.013
Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y, Yachida S (2013) Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg 258(2):336–346. https://doi.org/10.1097/SLA.0B013E3182827A65
Ott PA, Bang Y-J, Piha-Paul SA, Razak ARA, Bennouna J, Soria J-C, Rugo HS, Cohen RB, O’Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK (2019) T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with Pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol 37(4):318–327. https://doi.org/10.1200/JCO.2018.78.2276
Ottenhof NA, Morsink FHM, ten Kate F, van Noorden CJF, Offerhaus GJA (2012) Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only. Cell Oncol 35(2):119–126. https://doi.org/10.1007/S13402-012-0072-X/TABLES/4
Padua D, Massagué J (2008) Roles of TGFβ in metastasis. Cell Res 19(1):89–102. https://doi.org/10.1038/cr.2008.316
Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han SJ, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, el Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Mușină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J (2018) International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391(10135):2128–2139. https://doi.org/10.1016/S0140-6736(18)30789-X
Paijens ST, Vledder A, de Bruyn M, Nijman HW (2020) Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol 18(4):842–859. https://doi.org/10.1038/s41423-020-00565-9
Park W, Chawla A, O’Reilly EM (2021) Pancreatic cancer: a review. JAMA 326(9):851–862. https://doi.org/10.1001/JAMA.2021.13027
Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Nicole Li X, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW (2015) Phase I study of Pembrolizumab (MK-3475; anti–PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 21(19):4286–4293. https://doi.org/10.1158/1078-0432.CCR-14-2607
Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ (2014) Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother 63(7):721–735. https://doi.org/10.1007/S00262-014-1549-4
Pu N, Lou W, Yu J (2019) PD-1 immunotherapy in pancreatic cancer: current status. J Pancreatol 2(1):6–10. https://doi.org/10.1097/JP9.0000000000000010
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74(11):2913–2921. https://doi.org/10.1158/0008-5472.CAN-14-0155
Ratti M, Lampis A, Hahne JC, Passalacqua R, Valeri N (2018) Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci 75(22):4151. https://doi.org/10.1007/S00018-018-2906-9
Richman S (2015) Deficient mismatch repair: read all about it (review). Int J Oncol 47(4):1189–1202. https://doi.org/10.3892/IJO.2015.3119/HTML
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang Y-H, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T (2019) Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–1127. https://doi.org/10.1056/NEJMoa1816714
Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O (2018) Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer 18(1):688. https://doi.org/10.1186/s12885-018-4610-4
Shaib YH, El-Serag HB, Davila JA, Morgan R, Mcglynn KA (2005) Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128(3):620–626. https://doi.org/10.1053/J.GASTRO.2004.12.048
Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ (2007) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8(3):239–245. https://doi.org/10.1038/ni1443
Shi H, Li J, Fu D (2016) Process of hepatic metastasis from pancreatic cancer: biology with clinical significance. J Cancer Res Clin Oncol 142(6):1137–1161. https://doi.org/10.1007/s00432-015-2024-0
Shinto E, Omata J, Sikina A, Sekizawa A, Kajiwara Y, Hayashi K, Hashiguchi Y, Hase K, Ueno H (2020) Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer. BJS Open 4(2):301–309. https://doi.org/10.1002/BJS5.50251
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442
Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP (2018) Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 10:239–248. https://doi.org/10.2147/CMAR.S149619
Spechler SJ (2013) Barrett Esophagus and risk of esophageal cancer: a clinical review. JAMA 310(6):627–636. https://doi.org/10.1001/JAMA.2013.226450
Takeuchi Y, Nishikawa H (2016) Roles of regulatory T cells in cancer immunity. Int Immunol 28(8):401–409. https://doi.org/10.1093/intimm/dxw025
Tascilar M, Offerhaus GJA, Altink R, Argani P, Sohn TA, Yeo CJ, Cameron JL, Goggins M, Hruban RH, Wilentz RE (2001) Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct. Am J Clin Pathol 116(6):831–837. https://doi.org/10.1309/WF03-NFCE-7BRH-7C26
Teng F, Mu D, Meng X, Kong L, Zhu H, Liu S, Zhang J, Yu J (2015) Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer. Am J Cancer Res 5(6):2064
Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ (2017) Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 66(5):794–801. https://doi.org/10.1136/GUTJNL-2015-310839
Togashi Y, Shitara K, Nishikawa H (2019) Regulatory T cells in cancer immunosuppression – implications for anticancer therapy. Nat Rev Clin Oncol 16(6):356–371. https://doi.org/10.1038/s41571-019-0175-7
Tykodi SS (2014) PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther 7:1349–1359. https://doi.org/10.2147/OTT.S48443
Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 10:1269–1274. https://doi.org/10.1038/nm934
Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G (2012) Trial watch. OncoImmunology 1(2):179–188. https://doi.org/10.4161/ONCI.1.2.19026
van der Woude LL, Gorris MAJ, Halilovic A, Figdor CG, de Vries IJM (2017) Migrating into the tumor: a roadmap for T cells. Trends Cancer 3(11):797–808. https://doi.org/10.1016/j.trecan.2017.09.006
Villanueva A (2019) Hepatocellular carcinoma. 380(15):1450–1462. https://doi.org/10.1056/NEJMRA1713263
Voorneveld PW, Jacobs RJ, Kodach LL, Hardwick JCH (2015) A meta-analysis of SMAD4 immunohistochemistry as a prognostic marker in colorectal cancer. Transl Oncol 8(1):18. https://doi.org/10.1016/J.TRANON.2014.11.003
Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, Li X, Xiong W, Li G, Zeng Z, Guo C (2017a) Role of tumor microenvironment in tumorigenesis. J Cancer 8(5):761–773. https://doi.org/10.7150/jca.17648
Wang Q, Liu F, Liu L (2017b) Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis. Medicine (United States) 96:18. https://doi.org/10.1097/MD.0000000000006369
Wang X, Li X, Wei X, Jiang H, Lan C, Yang S, Wang H, Yang Y, Tian C, Xu Z, Zhang J, Hao J, Ren H (2020) PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. Signal Transduct Target Ther 5(1):1–12. https://doi.org/10.1038/s41392-020-0144-8
Waters AM, Der CJ (2018) KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med 8(9):a031435. https://doi.org/10.1101/CSHPERSPECT.A031435
Whatcott CJ, Posner RG, von Hoff DD, Han H (2012) Desmoplasia and chemoresistance in pancreatic cancer. In: Grippo PJ, Munshi HG (eds). Trivandrum (India)
Wu W, Liu Y, Zeng S, Han Y, Shen H (2021) Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes. J Hematol Oncol 14(1):1–28. https://doi.org/10.1186/S13045-021-01166-3
Xing S, Yang H, Liu J, Zheng X, Feng J, Li X, Li W (2016) Prognostic value of SMAD4 in pancreatic cancer: a meta-analysis. Transl Oncol 9(1):1. https://doi.org/10.1016/J.TRANON.2015.11.007
Yang J, Liu X, Cao S, Dong X, Rao S, Cai K (2020) Understanding esophageal cancer: the challenges and opportunities for the next decade. Front Oncol 10:1727. https://doi.org/10.3389/FONC.2020.01727/BIBTEX
Yang F, Deng K, Zheng H, Liu Z, Zheng Y (2022) Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing. Ann Hepatol 27(2):100677. https://doi.org/10.1016/J.AOHEP.2022.100677
Yi M, Niu M, Xu L, Luo S, Wu K (2021) Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol 14(1):1–13. https://doi.org/10.1186/S13045-020-01027-5
Yu CP, Fu SF, Chen X, Ye J, Ye Y, Kong LD, Zhu Z (2018) The clinicopathological and prognostic significance of IDO1 expression in human solid tumors: evidence from a systematic review and meta-analysis. Cell Physiol Biochem 49(1):134–143. https://doi.org/10.1159/000492849
Zhang J, Wang YF, Wu B, Zhong ZX, Wang KX, Yang LQ, Wang YQ, Li YQ, Gao J, Li ZS (2017) Intraepithelial attack rather than Intratumorally infiltration of CD8+T lymphocytes is a favorable prognostic indicator in pancreatic ductal adenocarcinoma. Curr Mol Med 17(10):689–698. https://doi.org/10.2174/1566524018666180308115705
Zhao J, Liang Y, Yin Q, Liu S, Wang Q, Tang Y, Cao C (2016) Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma. Braz J Med Biol Res 49:8. https://doi.org/10.1590/1414-431X20165485
Zheng L (2017) PD-L1 expression in pancreatic cancer. JNCI: J Natl Cancer Inst 109(6). https://doi.org/10.1093/JNCI/DJW304
Zheng X, Song X, Shao Y, Xu B, Hu W, Zhou Q, Chen L, Zhang D, Wu C, Jiang J (2018) Prognostic role of tumor-infiltrating lymphocytes in esophagus cancer: a meta-analysis. Cell Physiol Biochem 45(2):720–732. https://doi.org/10.1159/000487164
Zhu M, Jin Z, Hubbard JM (2021) Management of non-colorectal digestive cancers with microsatellite instability. Cancers 13(4):651. https://doi.org/10.3390/CANCERS13040651
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Orhan, A. (2022). Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_147-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-80962-1_147-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-80962-1
Online ISBN: 978-3-030-80962-1
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences